G01N 2333/70525
Icam molecules
Official title: ICAM molecules, e.g. CD50, CD54, CD102
G01N2333/70525 (Icam molecules) appears on 54 US grants and 140 published applications in this corpus.
Search patents in G01N- Granted patents
- 54
- Published applications
- 140
- Assignees
- 66
- Inventors
- 200
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 1 | 2 |
| 2009 | 0 | 3 |
| 2010 | 1 | 7 |
| 2011 | 1 | 6 |
| 2012 | 1 | 2 |
| 2013 | 1 | 4 |
| 2014 | 6 | 15 |
| 2015 | 4 | 22 |
| 2016 | 5 | 13 |
| 2017 | 6 | 12 |
| 2018 | 3 | 5 |
| 2019 | 2 | 6 |
| 2020 | 5 | 4 |
| 2021 | 4 | 11 |
| 2022 | 2 | 2 |
| 2023 | 1 | 5 |
| 2024 | 3 | 2 |
| 2025 | 4 | 4 |
| 2026 | 3 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Target for anti-cancer and immune-enhancing14 Apr 2026US 12,600,765 B2Genome and Company
- Compositions and methods for treatment24 Feb 2026US 12,558,350 B2Bausch + Lomb Ireland Limited
- Biomarkers for risk prediction of mortality6 Jan 2026US 12,517,139 B2Roche Diagnostics Operations, Inc.
- Adult stem cell compositions and methods of identification and isolation30 Dec 2025US 12,509,659 B2TACS Bio Inc.
- Method for detecting or treating triple negative breast cancer12 Aug 2025US 12,383,553 B2Children's Medical Center Corporation
- Chronic graft-versus-host disease (cgvhd) diagnostic and risk biomarker panels, methods and uses thereof13 Aug 2026US 2026/0235582 A1
- Novel target for anti-cancer and immune-enhancing2 Jul 2026US 2026/0184774 A1Genome and Company
- Fc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD549 Apr 2026US 2026/0098858 A1Navrogen, Inc.
- Adult stem cell compositions and methods of identification and isolation12 Mar 2026US 2026/0071178 A1TACS Bio Inc.
- Multi-protein biomarker assay for brain injury detection and outcome12 Feb 2026US 2026/0043814 A1The Johns Hopkins University
Most cited
By later US patents
- Compositions and methods for treatment of eye disorders84US 8,168,655 B2Sarcode Bioscience Inc. · 2012
- Compositions and methods for treatment of eye disorders29US 8,084,047 B2Sarcode Bioscience Inc. · 2011
- Compositions and methods for treatment of eye disorders26US 8,592,450 B2Sarcode Bioscience Inc. · 2013
- Atypical hemolytic uremic syndrome (AHUS) biomarker proteins11US 9,494,601 B2Alexion Pharmaceuticals, Inc. · 2016
- Methods for improving inflammatory bowel disease diagnosis9US 8,715,943 B2Nestec S. A. · 2014